Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
J Tenn Dent Assoc ; 95(1): 24-32; quiz 33-4, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26434000

RESUMO

Oral complications of cancer therapy can be so severe that they can lead to the discontinuation of cancer treatment. This can affect prognosis, patient survival, and alter patient quality of life. Early recognition and management of oral complications in cancer patients is a very important part of the overall treatment. Currently, a large number of cancers are treated at the ambulatory level, and when patients develop oral problems they may seek care from their private dentist. The goal of this manuscript is to discuss common oral complications of cancer therapy, and the role the general dentist can play in diagnosis and management.


Assuntos
Antineoplásicos/efeitos adversos , Doenças da Boca/etiologia , Neoplasias/terapia , Radioterapia/efeitos adversos , Humanos
2.
Cancer ; 104(1): 83-93, 2005 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-15929121

RESUMO

BACKGROUND: The current report presented 17 patients with cancer with bone metastases and 1 patient with osteopenia who received treatment with bisphosphonates and who subsequently developed osteonecrosis of the mandible and/or maxilla. METHODS: The authors reviewed information on 18 patients who were referred to oral medicine or oral surgery specialists for evaluation and treatment of mandibular and/or maxillary bone necrosis from June 2002 to September 2004. To be included in the current review, patients must have been treated with either pamidronate or zoledronic acid to control or prevent metastatic disease, or with alendronate for osteoporosis. All patients with cancer had received chemotherapy while receiving bisphosphonate management. RESULTS: The 17 patients with cancer were receiving active medical care for a malignancy. Cancer treatment included a variety of chemotherapeutic agents. They presented with metastatic disease to bone and were treated intravenously with the bisphosphonates pamidronate or zoledronic acid for a mean time of 25 months (range, 4-41 mos). There were 14 females and 4 males with a mean age of 62 years (range, 37-74 yrs). Malignancies included breast carcinoma (n = 10), multiple myeloma (n = 3), prostate carcinoma (n = 1), ovarian carcinoma (n = 1), prostate carcinoma/lymphoma (n = 1), and breast/ovarian carcinoma (n = 1). One female patient with osteopenia received alendronate. The most common clinical osteonecrosis presentations included infection and necrotic bone in the mandible. Associated events included dental extractions, infection, and trauma. Two patients appeared to develop disease spontaneously, without any clinical or radiographic evidence of local pathology. Despite surgical intervention, antibiotic therapy, hyperbaric oxygen therapy, and topical use of chemotherapeutic mouth rinses, most of the lesions did not respond well to therapy. Discontinuation of bisphosphonate therapy did not assure healing. However, 1 patient with cancer healed after discontinuation of bisphosphonate therapy for 4 months. CONCLUSIONS: The findings in the patient population combined with recent literature reports suggested that bisphosphonates may contribute to the pathogenesis of the oral lesions. The risk factors and precise mechanism involved in the formation of the osteonecrosis are not known. This condition represents a new oral complication in patients with cancer and can be termed bisphosphonate-associated osteonecrosis. Lesions in patients with osteoporosis are worrisome and need to be further evaluated.


Assuntos
Neoplasias Ósseas/tratamento farmacológico , Neoplasias Ósseas/secundário , Difosfonatos/efeitos adversos , Doenças Mandibulares/induzido quimicamente , Doenças Maxilares/induzido quimicamente , Osteonecrose/induzido quimicamente , Adulto , Idoso , Doenças Ósseas Metabólicas/tratamento farmacológico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
3.
Rev. paul. pediatr ; 12(2): 258-63, jul. 1994. ilus
Artigo em Português | LILACS | ID: lil-218975

RESUMO

Os autores apresentam três casos clínicos em que relatam o efeito do tratamento oncológico, utilizando quimioterapia (QT) e radioterapia (RTX) em crianças com idades entre 3 meses e 5 anos. O tratamento radioterápico leva a anormalidades do desenvolvimento crânio-facial, como hipodesenvolvimento maxilar e/ou mandibular, formaçäo de estruturas anômalas mineralizadas. Tanto a QT como a RXT levam a alteraçöes na odontogênese, hipoplasia de esmalte, parada de desenvolvimento do órgäo dentário, näo-formaçäo de dentes, microdontias, alteraçöes na rizogênese, tais como interrupçäo, afilamento, alargamento da câmara pulpar, efeitos estes que säo mais acentuados quando se encontram associados as duas formas terapêuticas


Assuntos
Humanos , Masculino , Feminino , Pré-Escolar , Radioterapia/efeitos adversos , Tratamento Farmacológico/efeitos adversos , Neoplasias/complicações , Cárie Dentária/etiologia , Doenças da Boca/etiologia , Neoplasias/terapia , Doenças da Boca/prevenção & controle
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa